Clinical, cosmetic and investigational dermatology · 2022
Tofacitinib for the Treatment of Steroid-Induced Rosacea.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Tianhao, Wang Henghong, Wang Caiying, Hao Pingsheng
Аннотация
PURPOSE: Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored.
PATIENTS AND METHODS: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.
RESULTS: This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR.
CONCLUSION: JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.
PATIENTS AND METHODS: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.
RESULTS: This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR.
CONCLUSION: JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.